TP53 and breast neoplasm: Moreover, HER2-zero breast tumors had significantly higher mutation rates in TP53 (p < 0.01), telomerase reverse transcriptase (TERT; p < 0.05), polypeptide N-acetylgalactosaminyltransferase 12 (GALNT12; p < 0.05), caspase recruitment domain family member 11 (CARD11; p < 0.05), and transformation/transcription domain-associated protein (TRRAP; p < 0.05) than HER2-low tumors (Fig. 3C, Additional file 1: Fig. S2C).